545 reports of this reaction
1.3% of all METHYLPREDNISOLONE ACETATE reports
#20 most reported adverse reaction
HYPERHIDROSIS is the #20 most commonly reported adverse reaction for METHYLPREDNISOLONE ACETATE, manufactured by Pharmacia & Upjohn Company LLC. There are 545 FDA adverse event reports linking METHYLPREDNISOLONE ACETATE to HYPERHIDROSIS. This represents approximately 1.3% of all 42,188 adverse event reports for this drug.
Patients taking METHYLPREDNISOLONE ACETATE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for METHYLPREDNISOLONE ACETATE, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for METHYLPREDNISOLONE ACETATE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 545 FDA reports for METHYLPREDNISOLONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.3% of all adverse event reports for METHYLPREDNISOLONE ACETATE, making it a notable side effect.
If you experience hyperhidrosis while taking METHYLPREDNISOLONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.